- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Sandra Stein on the Important Issue of Social Determinants of Health
After moderating the panel discussion at The American Journal of Managed Care®’s Institute for Value-Based Medicine® (IVBM) event held in partnership with Banner|Aetna, Sandra Stein, MD, chief medical officer of Banner Health Plans, shared her key takeaway.
After moderating the panel discussion at The American Journal of Managed Care®’s Institute for Value-Based Medicine® (IVBM) event held in partnership with Banner|Aetna, Sandra Stein, MD, chief medical officer of Banner Health Plans, shared her key takeaway.
Transcript
As part of the panel discussion on ideas from “Health Systems and Social Services: A Bridge Too Far?” in which the authors disagreed that health systems should invest in social determinants of health, what points stood out to you?
The points that stood out to me the most were that there was a very diverse health care group represented. And I think I spoke to the point, everybody was on the same page about how important an issue this is and that social determinants of health need to be addressed in coordination with health care. It was that call to action to really figure out how we do this—there may be different ways to do it within the diverse group that we're talking about, but overall, we need to look at things from a high-level perspective and how we work together. Otherwise, we aren’t going to be able to have that profound impact that we really owe our health care communities.
Increased Interest in Advance Provision and Over-the-Counter Medication Abortion
January 16th 2025An increased public interest and support for medication abortion following the federal Supreme Court ruling, particularly among marginalized groups, suggests a shift towards more accessible and autonomous models of abortion care.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
The study found significant disparities in the exposure to contaminants. Communities with higher percentages of Hispanic and Black residents were not only more likely to have unregulated chemicals in their drinking water, but they were also more frequently located near pollution sources.
Read More
Study Suggests Postdischarge Care Needs Targeted, Multifaceted Approaches
January 15th 2025The findings challenge the effectiveness of these widely used transitional care interventions and suggest a need for more targeted, multifaceted approaches to address the needs of higher-risk patients.
Read More
